Press Releases

2020

July 07, 2020
KSQ Therapeutics Announces Leadership Changes

June 22, 2020
AACR Poster Presentation: "KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors

May 12, 2020
ASGCT Poster Presentation: "Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)"

February 09, 2020
KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

2019

December 04, 2019
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

December 03, 2019
KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

November 12, 2019
KSQ Therapeutics Enhances Board of Directors with Two Appointments

November 09, 2019
SITC Poster Presentation: "An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets"

October 29, 2019
EORTC Poster Presentation: "Comprehensive Identification of Novel Therapeutic Targets for Treatment of PD-1 Resistant Solid Tumors via a Genome-Scale CRISPR/cas9 in vivo T-cell Screen"

October 28, 2019
KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine

October 15, 2019
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

April 16, 2019
KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer

April 16, 2019
KSQ Therapeutics Announces Appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer

2018

September 28, 2018
KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors

September 25, 2018
KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors

2017

October 02, 2017
KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development